Sunmax Biotechnology Co

Sunmax Biotechnology Co EPS

The Earnings per Share (EPS) of Sunmax Biotechnology Co (4728.TWO) as of Nov 3, 2026 is 13.33 TWD. In the previous year, Earnings per Share (EPS) was 12.48 TWD — a change of 6.79% (higher).

EPS

13.33TWD

YoY

6.79%

Last updated:

Earnings per Share (EPS) of Sunmax Biotechnology Co is 2025 13.33 TWD. Earnings per Share (EPS) of Sunmax Biotechnology Co was 2024 12.48 TWD. It decreases by 6.79% higher compared to the previous year.

The Sunmax Biotechnology Co EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2018
1.37 TWD
Jan 1, 2019
1.84 TWD
Jan 1, 2020
4.37 TWD
Jan 1, 2021
4.51 TWD
Jan 1, 2022
9.80 TWD
Jan 1, 2023
11.47 TWD
Jan 1, 2024
12.48 TWD
Jan 1, 2025
13.33 TWD
The Sunmax Biotechnology Co EPS history
YEAREPSYoY
13.33TWD+6.79%
12.48TWD+8.76%
11.47TWD+17.05%
9.80TWD+117.32%
4.51TWD+3.18%
4.37TWD+137.02%
1.84TWD+34.54%
1.37TWD+347.70%
0.31TWD+856.17%
0.03TWD-103.95%
-0.81TWD-318.23%
0.37TWD-57.97%
0.88TWD+195.53%
0.30TWD-75.74%
1.23TWD+120.88%
0.56TWD-339.04%
-0.23TWD-72.26%
-0.84TWD-33.39%
-1.26TWD-44.74%
-2.29TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sunmax Biotechnology Co Stock analysis

What does Sunmax Biotechnology Co do? SunMax Biotechnology Co., Ltd. generates revenue through the development, manufacturing, and commercialization of medical devices, biomedical materials, and bio surgical products. Its major products include collagen, collagen implants, microfiber collagen hemostat, collagen absorbable hemostat pads, healthcare products, and medical collagen application equipment. These products are sold to customers in the medical and beauty care industries across Taiwan, Mainland China, and other regions. The company's distribution focuses on these key markets, leveraging its product portfolio for healthcare and aesthetic applications. The firm's product line targets both medical and beauty care sectors, with collagen-based solutions serving as core offerings. Medical collagen application equipment supports clinical procedures, while collagen implants and hemostat products address surgical and wound care needs. The company's presence in Taiwan, Mainland China, and other regions enables it to serve diverse healthcare markets with standardized product offerings. SunMax Biotechnology's revenue streams are derived from the sale of collagen-based medical devices and equipment, with a focus on applications in surgery, wound care, and aesthetic treatments. By distributing its products through established channels in Taiwan, Mainland China, and other regions, the company capitalizes on demand for biocompatible materials in healthcare and beauty care industries. Sunmax Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sunmax Biotechnology Co stock

Earnings per Share (EPS) of Sunmax Biotechnology Co is 13.33 TWD in 2025.

Earnings per Share (EPS) of Sunmax Biotechnology Co changed from 12.48 TWD to 13.33 TWD, representing a 6.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Sunmax Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Sunmax Biotechnology Co

All Key Metrics — Sunmax Biotechnology Co